EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance

Chris J Packard iD, Angela Pirillo iD, Sotirios Tsimikas, Brian A Ference, Alberico L Catapano iD

Cardiovascular Research · 17.02.2024 · 119 (18) · 2843-2857

DOI: 10.1093/cvr/cvad177 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 01.12.2023. Verfasst von Chris J Packard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Atherosclerosis, Coronary Disease. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NHLBI, Fondation Leducq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The availability of pharmacological approaches able to effectively reduce circulating LDL cholesterol (LDL-C) has led to a substantial reduction in the risk of atherosclerosis-related cardiovascular disease (CVD). However, a residual cardiovascular (CV) risk persists in treated individuals with optimal levels of LDL-C. Additional risk factors beyond LDL-C are involved, and among these, elevated levels of triglycerides (TGs) and TG-rich lipoproteins are causally associated with an increased CV risk. Apolipoprotein C-III (apoC-III) is a key regulator of TG metabolism and hence circulating levels through several mechanisms including the inhibition of lipoprotein lipase activity and alterations in the affinity of apoC-III-containing lipoproteins for both the hepatic receptors involved in their removal and extracellular matrix in the arterial wall. Genetic studies have clarified the role of apoC-III in humans, establishing a causal link with CVD and showing that loss-of-function mutations in the APOC3 gene are associated with reduced TG levels and reduced risk of coronary heart disease. Currently available hypolipidaemic drugs can reduce TG levels, although to a limited extent. Substantial reductions in TG levels can be obtained with new drugs that target specifically apoC-III; these include two antisense oligonucleotides, one small interfering RNA and an antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCoronary DiseaseHumansApolipoprotein C-IIICholesterol, LDLLipoproteinsTriglycerides

Stichwörter der Autor:innen

Apolipoprotein C-IIICardiovascular diseaseGeneticsTriglyceride-rich lipoproteinsTriglycerides

Substanzen

Apolipoprotein C-IIICholesterol, LDLLipoproteinsTriglyceridesAPOC3 protein, human

Autor:innen und Institutionen

  • Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Center for the Study of Atherosclerosis, E. Bassini Hospital, Milan, Italy.
  • Center for the Study of Dyslipidaemias, IRCCS MultiMedica, Sesto S. Giovanni, 20099 Milan, Italy.
  • Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA, USA.
  • Centre for Naturally Randomized Trials, University of Cambridge, Cambridge, UK.
  • Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milan, Italy.

ORCID-Profile: Chris J Packard, Angela Pirillo, Alberico L Catapano

Förderung

  • NHLBI NIH HHS
  • NHLBI
  • Fondation Leducq
  • Italian Ministry of Health
  • NIH

Zitieren

APA

Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024). Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance. Cardiovascular Research, 119(18), 2843-2857. https://doi.org/10.1093/cvr/cvad177

Vancouver

Packard CJ, Pirillo A, Tsimikas S, Ference BA, Catapano AL. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance. Cardiovascular Research. 2024;119(18):2843-2857. doi:10.1093/cvr/cvad177

BibTeX
@article{Packard2024,
  author = {Packard, Chris J and Pirillo, Angela and Tsimikas, Sotirios and Ference, Brian A and Catapano, Alberico L},
  title = {Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {119},
  number = {18},
  pages = {2843--2857},
  doi = {10.1093/cvr/cvad177}
}
Kostenlos starten →